ArticlePloS one2011
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02160730 (Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Architects of Pituitary Tumour Growth.Frontiers in endocrinology · 2022Review
- Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.Neuro-oncology · 2021Article
- Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.The EPMA journal · 2021Review
- Attenuation of MAMLD1 Expression Suppresses the Growth and Migratory Properties of Gonadotroph Pituitary Adenomas.Pathology oncology research : POR · 2020Article
- A Novel Expression Profile of Cell Cycle and DNA Repair Proteins in Nonfunctioning Pituitary Adenomas.Endocrine pathology · 2020Article
- Pathogenesis of non-functioning pituitary adenomas.Pituitary · 2018Review
- Bioinformatic analysis of gene expression profiles of pituitary gonadotroph adenomas.Oncology letters · 2018Article
- Autocrine IL-6 mediates pituitary tumor senescence.Oncotarget · 2017Article
- Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells.OncoTargets and therapy · 2017Article
- Prolactinomas: evolution after menopause.Archives of endocrinology and metabolism · 2016Article
- Article
- Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells.Pituitary · 2015Article
- Pituitary tumors.Endocrinology and metabolism clinics of North America · 2015Review
- A structural and functional acromegaly classification.The Journal of clinical endocrinology and metabolism · 2015Article
- Regulation of LH/FSH expression by secretoglobin 3A2 in the mouse pituitary gland.Cell and tissue research · 2014Article
- Growth hormone is a cellular senescence target in pituitary and nonpituitary cells.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Silencing of RASSF3 by DNA hypermethylation is associated with tumorigenesis in somatotroph adenomas.PloS one · 2013Article
- Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth.Molecular endocrinology (Baltimore, Md.) · 2012Article
- PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas.Endocrine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Although pituitary adenomas are usually benign, unique trophic mechanisms restraining cell proliferation are unclear. As GH-secreting adenomas are associated with p53/p21-dependent senescence, we tested mechanisms constraining non-functioning pituitary adenoma growth. Thirty six gonadotroph-derived non-functioning pituitary adenomas all exhibited DNA damage, but undetectable p21 expression. However, these adenomas all expressed p16, and >90% abundantly expressed cytoplasmic clusterin associated with induction of the Cdk inhibitor p15 in 70% of gonadotroph and in 26% of somatotroph lineage adenomas (p = 0.006). Murine LβT2 and αT3 gonadotroph pituitary cells, and αGSU.PTTG transgenic mice with targeted gonadotroph cell adenomas also abundantly expressed clusterin and exhibited features of oncogene-induced senescence as evidenced by C/EBPβ and C/EBPδ induction. In turn, C/EBPs activated the clusterin promoter ∼5 fold, and elevated clusterin subsequently elicited p15 and p16 expression, acting to arrest murine gonadotroph cell proliferation. In contrast, specific clusterin suppression by RNAis enhanced gonadotroph proliferation. FOXL2, a tissue-specific gonadotroph lineage factor, also induced the clusterin promoter ∼3 fold in αT3 pituitary cells. As nine of 12 pituitary carcinomas were devoid of clusterin expression, this protein may limit proliferation of benign adenomatous pituitary cells. These results point to lineage-specific pathways restricting uncontrolled murine and human pituitary gonadotroph adenoma cell growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.